Voglibose, an Alpha-glucosidase Inhibitor, to Increase Active Glucagon-like Peptide-1 Levels
|
|
- Marion Wilson
- 6 years ago
- Views:
Transcription
1 PharmSight TM DOI: /mcpharmacol Molecular and Cellular Pharmacology Voglibose, an Alpha-glucosidase Inhibitor, to Increase Active Glucagon-like Peptide-1 Levels Yusuke Moritoh 1, Koji Takeuchi 1 and Masatoshi Hazama 2 1 Pharmacology Research Laboratories and 2 Strategic Research Planning Department, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Osaka, Japan PharmSight on Moritoh Y, et al. Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice. J Pharamacol Exp Ther 2009;329: Abstract Voglibose is an alpha-glucosidase inhibitor used for lowering post-prandial blood glucose levels in patients with diabetes mellitus. Voglibose is known for its ability to increase glucagon-like peptide-1 (GLP-1) secretion in humans. Our recent study demonstrated new mechanisms by which voglibose increases plasma active GLP-1 levels in diabetic ob/ob mice. As expected, the stimulatory effects of voglibose on GLP-1 secretion resulted in increased active GLP-1 levels in plasma in the 1- day dosing study. Unexpectedly, chronic but not 1- day treatment with voglibose decreased plasma dipeptidyl peptidase-4 (DPP-4) activity by reducing its circulating protein levels. We have also revealed that chronic dosing of voglibose increased Neurod1 and Glucagon gene expression, and GLP- 1 content in the lower gut. Active GLP-1 levels in plasma achieved by chronic treatment with voglibose were higher than those achieved by 1- day treatment. In the present overview, by using acarbose, another alpha-glucosidase inhibitor with different selectivity, as a comparator, we demonstrated that inhibition of alpha-glucosidase induces a decrease in plasma DPP-4 activity in ob/ob mice. Notably, compared to acarbose, voglibose has demonstrated more favorable effects on DPP-4 activity, GLP-1 secretion and gut GLP-1 content, when glucose levels were equally improved, leading to higher plasma active GLP-1 levels. These findings provide new insights into Received 08/10/09; accepted 09/11/09 Correspondence: Yusuke Moritoh, Pharmacology Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka , Japan. Tel , Fax moritou_yuusuke@takeda.co.jp the mechanism underlying the increases in active GLP-1 circulation by voglibose. Keywords: Dipeptidyl peptidase-4; Glucagon-like peptide-1; Voglibose Introduction Alpha-glucosidase inhibitors delay the breakdown of carbohydrates in the small intestine and thus diminish the postprandial increase of blood glucose levels in animals and humans (1-3). Voglibose, acarbose, and miglitol are commonly used in clinical practice (1-3). One intriguing aspect of the alpha-glucosidase inhibitor is its ability to both increase and prolong glucagon-like peptide-1 (GLP-1) secretion in normal individuals and patients with type 2 diabetes (4-10). GLP-1 (7-36) amide and GLP- 1 (7-37), both of which are active forms of GLP-1 and have similar activity, are secreted from gut L-cells (11). GLP-1 is now known to be involved in the regulation of insulin secretion (12), glucagon secretion (13), beta-cell turn-over (14), and extrapancreatic tissue functions (15). The active forms of GLP-1 are rapidly broken down by the enzyme dipeptidyl peptidase-4 (DPP-4) (16), leading to the generation of the inactive forms, GLP-1 (9-36) amide and GLP-1 (9-37) (16). Preclinical and clinical studies have demonstrated that activating GLP-1 signals by administration of GLP-1 receptor agonists or DPP-4 inhibitors can improve diabetes in animals and humans (17-20). Alpha-glucosidase inhibitors delay carbohydrate absorption, which results in an increase in sugar absorption in the lower gut (21). Taking into account that sugar absorption plays a critical role on GLP-1 secretion (22, 23) and that 188
2 189 Voglibose and Glucagon-like Peptide-1 Levels GLP-1 producing cells are abundant in the lower gut (24, 25), delayed carbohydrate absorption is considered to be an acceptable contributing factor for stimulating GLP-1 secretion by alphaglucosidase inhibition. However the mechanism by which alpha-glucosidase inhibitors increase GLP-1 secretion is poorly understood. In addition, limited data is available in regards to the effects of alphaglucosidase inhibition on active forms of GLP-1 levels. Results and Discussion We recently found that voglibose has previouslyunreported mechanisms by which it increases active GLP-1 levels in diabetic ob/ob mice (24). When administered in the diet to ob/ob mice for 1-day, voglibose at doses of 0.001% and 0.005% showed no effect on plasma DPP-4 activity as expected (24). This is consistent with the fact that voglibose had no effect on DPP-4 activity in vitro (24). However, 1-day treatment of voglibose resulted in increase in plasma active GLP-1 levels (0.001% voglibose, 8.0±2.0 pm; 0.005% voglibose, 16.6±7.8 pm; vehicle, 4.9±3.0 pm) in ob/ob mice (24). Taken together, these results indicate that a stimulatory effect on GLP-1 secretion but not a direct inhibition of the DPP-4 enzyme may contribute to the increase in active GLP-1 levels by voglibose. Interestingly when administered chronically (3-4 weeks), voglibose showed an unexpected effect on plasma DPP-4 profiles. Chronic administration of voglibose resulted in a 40-51% decrease in plasma DPP-4 activity (24). The measurement of plasma DPP-4 protein concentration revealed that voglibose decreased its plasma concentrations by 31-43% (24). These results indicated that it was the ability of voglibose to decrease the circulating DPP-4 protein that resulted in the corresponding decrease in plasma DPP-4 activity. The 40-51% decrease in plasma DPP-4 activity, which was observed in voglibose-treated ob/ob mice, was likely to be sufficient to increase plasma active GLP-1 levels. In fact, around 30% DPP-4 inhibition by the DPP-4 inhibitor alogliptin significantly increased plasma active GLP-1 levels in ob/ob mice (20). As expected, the chronic treatment of voglibose produced higher levels of plasma active GLP-1 (11.4±3.9 and 24.4±6.7 pm by 0.001% and 0.005% voglibose, respectively. 6.0±1.4 pm by vehicle) compared with the 1-day treatment with voglibose (8.0±2.0 and 16.6±7.8 pm by 0.001% and 0.005% voglibose, respectively. 4.9±3.0 pm by vehicle) (24). A similar treatment with 0.001% and 0.005% voglibose for 3-4 weeks had no effects on plasma DPP-4 activity in normal control mice, which showed lower plasma DPP-4 activity compared with ob/ob mice, indicating that the voglibose-induced decrease in plasma DPP-4 activity may be specific to diabetic ob/ob mice. Administration of pioglitazone (0.03% in the diet), a peroxisome proliferator-activated receptor gamma agonist, resulted in significantly improved glucose levels that were comparable to the glucose levels achieved by voglibose (0.005% in the diet) (24). However, pioglitazone was unable to alter the DPP-4 concentration and activity (24), indicating that improving glucose control is not the primary means by which plasma DPP-4 concentration and activity are altered in ob/ob mice. Thus, the mechanism by which voglibose decreases plasma DPP-4 concentration remains to be determined. Chronic treatment of voglibose also had an impact on enteroendocrine cells, which may contribute to the observed increase in plasma active GLP-1 levels (24). Once again, it was unexpectedly observed that chronic treatment with voglibose resulted in an increase in active GLP-1 content in the lower intestine (1.5- to 1.6-fold increase) and colon (1.4- to 1.6-fold increase) (24). The increased active GLP-1 content in the colon was positively correlated with an increase in gut gene expression levels of Neurod1 (1.3- to 1.4-fold increase) and Glucagon (2.6- to 3.1-fold increase) (24). The increased gene expression of Neurod1, which is known to be an essential regulator for enteroendocrine cell differentiation (26), suggests that voglibose may induce differentiation of enteroendocrine cells. A recent study has shown that oligofructose, a dietary nondigestible carbohydrate, promoted L-cell differentiation as evidenced by the increased number of L-cells, elevated Glucagon gene expression, and a doubling of GLP-1 content in the proximal colon in rats (27). Thus, voglibosegenerated undigested carbohydrates may play a role in the increase in gene expression of Neurod1 and Glucagon, and GLP-1 content in the lower gut. Further analysis into the complete mechanism is still warranted. To assess whether our observations are a class effect by alpha-glucosidase inhibitors, the effects of acarbose, another alpha-glucosidase inhibitor, were compared with those of voglibose in ob/ob mice. The doses for acarbose were 0.05% and 0.5% in the diet, which exhibited comparable efficacy at lowering glucose levels to that of 0.001% and 0.005% of voglibose in ob/ob mice. Although it was weaker
3 Voglibose and Glucagon-like Peptide-1 Levels 190 Voglibose H O HO HO N H No direct inhibition on DPP-4 Short-term (1 day) Long-term Plasma DPP-4 activity Plasma DPP-4 protein GLP-1 secretion Gut GLP-1 content* Gut Neurod1 and Glucagon gene expression Plasma active GLP-1 Figure 1. Schematic diagram of effects of short-term or long-term treatment with voglibose in ob/ob mice. Short-term (1-day) treatment with voglibose had no effect on plasma DPP-4 activity. However, 1-day treatment with voglibose increased GLP-1 secretion, leading to increase in plasma active GLP-1 levels. Chronic administration of voglibose decreased plasma DPP-4 activity by reducing plasma DPP-4 protein levels. In addition to enhancing GLP-1 secretion, chronic treatment with voglibose increased GLP-1 content in the lower gut, which was positively correlated with an increase in gut gene expression levels of Neurod1 and Glucagon. These observation leads to higher plasma active GLP-1 levels in ob/ob mice. * One-day effect of voglibose on gut GLP-1 content was not tested. than the effect of voglibose, chronic treatment with acarbose also dose dependently decreased plasma DPP-4 concentration (-27 to -37%) and activity (-27 to -43%) in ob/ob mice. In addition, in vitro DPP-4 assay revealed no direct inhibition of acarbose on DPP-4 activity. Taken together with the voglibose results, alpha-glucosidase inhibition may result in decreased plasma DPP-4 concentration and activity in ob/ob mice by some common mechanisms. A notable difference was, however, observed in the plasma active GLP-1 levels between voglibose and acarbose after 1-day and chronic treatment. Acarbose increased plasma active GLP-1 levels after 1-day treatment with 0.05% and 0.5% doses while this regimen had no effect on plasma DPP-4 activity as expected. The active GLP-1 levels produced by acarbose (6.5±1.3 pm by 0.05% acarbose and 7.8±1.0 pm by 0.5% acarbose) were unexpectedly lower
4 191 Voglibose and Glucagon-like Peptide-1 Levels compared to voglibose (0.001% voglibose, 8.0±2.0 pm; 0.005% voglibose, 16.6±7.8 pm; vehicle, 4.9±3.0 pm). When administered chronically, low-dose acarbose (0.05%) administration produced 9.0±6.1 pm of plasma active GLP-1 levels (6.0±1.4 pm by vehicle). While high dose administration of acarbose (0.5% in the diet) resulted in superior glucose control compared with the lower dose, it still resulted in only 9.0±5.4 pm of plasma active GLP-1 levels. These results indicate that voglibose may have a more favorable effect on increasing active GLP-1 levels compared with acarbose. When total amide GLP-1 levels (intact plus N-terminal-degraded amide GLP-1) were measured, 0.001% and 0.005% voglibose induced 1.3- and 1.5-fold increases in plasma amide GLP-1 levels, respectively, compared with vehicle alone (24). The administration of 0.05% acarbose increased amide GLP-1 levels by 1.2-fold, whereas 0.5% acarbose induced only 1.1-fold increase in amide GLP-1 levels, compared with vehicle alone. Consistently, in normal control mice, administration of 0.5% acarbose decreased amide GLP-1 levels by 46%, compared with vehicle-treated normal mice. These results indicate that voglibose may have a stronger effect on GLP-1 secretion compared with acarbose in ob/ob mice. We speculate that the differences in enzymatic specificities of voglibose and acarbose against several types of glucosidase enzymes (2), leading to the different composition of undigested carbohydrates in the gut, may be a possible reason for the variability in GLP-1 secretion. When animal feces were compared, voglibose-treatment produced black feces, similar to that of vehicle treated mice, although somewhat smaller. The feces of acarbosetreated ob/ob mice were brown in color and little larger than vehicle-treated mice. Acarbose inhibits alpha-amylase thereby inhibiting the degradation of chow-derived starch, whereas voglibose has a much weaker effect on alpha-amylase when given in a pharmacologically effective range (2). Thus undigested starch is likely to be included in the brown feces in acarbose-treated mice. In a previous report, complex carbohydrates, like boiled brown rice or barley, were unable to stimulate GLP-1 secretion in contrast to a glucose meal, which clearly enhanced GLP-1 secretion in healthy human subjects (28). By contrast, sucrose and maltose, both of which are disaccharides, had stimulatory effects on GLP-1 secretion in the ileal loops of anaesthetized dogs (29). Thus, the lack of inhibitory activity of voglibose on alpha-amylase activity, which seems to generate more disaccharides in the lower gut than acarbose, may contribute to the increase in GLP-1 secretion in ob/ob mice. In addition, unlike voglibose, acarbose was unable to increase active GLP-1 content in the lower-intestine in our ob/ob mouse study (vehicle, 106±28; 0.05% acarbose, 114±18; 0.5% acarbose, 116±12; 0.001% voglibose, 158±21; 0.005% voglibose, 166±31 pmol/g gut weight). Furthermore, our study demonstrated that colon active GLP-1 content in acarbose-treated mice was lower compared to voglibose-treated ob/ob mice (vehicle, 194±11; 0.05% acarbose, 246±46; 0.5% acarbose, 256±38; 0.001% voglibose, 279±45; 0.005% voglibose, 307±25 pmol/g gut weight). This corresponded with the results that suggested that acarbose had lower efficacy at increasing Glucagon gene expression in the colon (1.8- to 2.3-fold increase by acarbose, and 2.6- to 3.1- fold increase by voglibose). Taken together, these results suggest that the ability of voglibose to increase GLP-1 secretion and gut GLP-1 content accompanied with decreasing plasma DPP-4 activity may explain the reason why voglibose exhibits a more favorable effect on increasing plasma active GLP-1 levels compared to acarbose in ob/ob mice (Figure 1). In conclusion, our studies showed that the acute and chronic effects of voglibose on DPP-4 differ; chronic but not 1-day administration of voglibose decreased plasma DPP-4 activity by reducing its circulating levels in plasma. In addition, chronic treatment with voglibose increased GLP-1 secretion and elevated GLP-1 content in the lower gut. Collectively, chronic administration of voglibose resulted in an increase in plasma active GLP-1 levels, which were higher compared with those achieved by acarbose. These observations suggest that voglibose may have additional utility in the management of type 2 diabetes. Acknowledgements The authors would like to thank Michelle Kujawski for writing support and comments on the manuscript. Conflicts of Interest No potential conflicts of interest to disclose. References 1. Scheen AJ. Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus? Drugs 2003;63:
5 Voglibose and Glucagon-like Peptide-1 Levels Matsuo T, Odaka H, Ikeda H. Effect of an intestinal disaccharidase inhibitor (AO-128) on obesity and diabetes. Am J Clin Nutr 1992;55(1 Suppl):314S-7S. 3. Sudhir R, Mohan V. Postprandial hyperglycemia in patients with type 2 diabetes mellitus. Treat Endocrinol 2002;1: Qualmann C, Nauck MA, Holst JJ, Orskov C, Creutzfeldt W. Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using alpha-glucosidase inhibition (acarbose). Scand J Gastroenterol 1995;30: Ranganath L, Norris F, Morgan L, Wright J, Marks V. Delayed gastric emptying occurs following acarbose administration and is a further mechanism for its antihyperglycaemic effect. Diabet Med 1998;15: Enc FY, Imeryuz N, Akin L, Turoglu T, Dede F, Haklar G, et al. Inhibition of gastric emptying by acarbose is correlated with GLP-1 response and accompanied by CCK release. Am J Physiol Gastrointest Liver Physiol 2001;281:G Seifarth C, Bergmann J, Holst JJ, Ritzel R, Schmiegel W, Nauck MA. Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients. Diabet Med 1998;15: Fukase N, Takahashi H, Manaka H, Igarashi M, Yamatani K, Daimon M, et al. Differences in glucagon-like peptide-1 and GIP responses following sucrose ingestion. Diabetes Res Clin Pract 1992;15: Lee A, Patrick P, Wishart J, Horowitz M, Morley JE. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics. Diabetes Obes Metab 2002;4: Goke B, Fuder H, Wieckhorst G, Theiss U, Stridde E, Littke T, et al. Voglibose (AO-128) is an efficient alphaglucosidase inhibitor and mobilizes the endogenous GLP-1 reserve. Digestion 1995;56: Orskov C, Wettergren A, Holst JJ. Biological effects and metabolic rates of glucagonlike peptide amide and glucagonlike peptide in healthy subjects are indistinguishable. Diabetes 1993;42: Holst JJ. On the physiology of GIP and GLP-1. Horm Metab Res. 2004;36: Gromada J, Rorsman P. New insights into the regulation of glucagon secretion by glucagon-like peptide-1. Horm Metab Res 2004;36: Perfetti R, Hui H. The role of GLP-1 in the life and death of pancreatic beta cells. Horm Metab Res 2004;36: Ahren B. GLP-1 and extra-islet effects. Horm Metab Res 2004;36: Lambeir AM, Durinx C, Scharpe S, De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003;40: Holst JJ, Vilsboll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 2009;297: Gilbert MP, Pratley RE. Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus. Am J Med 2009;122(6 Suppl):S Moritoh Y, Takeuchi K, Asakawa T, Kataoka O, Odaka H. Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice. Br J Pharmacol 2009;157: Moritoh Y, Takeuchi K, Asakawa T, Kataoka O, Odaka H. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice. Eur J Pharmacol 2008;588: Goto Y, Yamada K, Ohyama T, Matsuo T, Odaka H, Ikeda H. An alpha-glucosidase inhibitor, AO-128, retards carbohydrate absorption in rats and humans. Diabetes Res Clin Pract 1995;28: Gribble FM, Williams L, Simpson AK, Reimann F. A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line. Diabetes 2003;52: Tolhurst G, Reimann F, Gribble FM. Nutritional regulation of glucagon-like peptide-1 secretion. J Physiol 2009;587(Pt 1): Moritoh Y, Takeuchi K, Hazama M. Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice. J Pharmacol Exp Ther 2009;329: Nauck MA. Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective. Acta Diabetol 1998;35: Schonhoff SE, Giel-Moloney M, Leiter AB. Minireview: Development and differentiation of gut endocrine cells. Endocrinology 2004;145: Cani PD, Hoste S, Guiot Y, Delzenne NM. Dietary non-digestible carbohydrates promote L-cell differentiation in the proximal colon of rats. Br J Nutr 2007;98: Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J, Marks V. Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J Endocrinol 1993;138: Shima K, Suda T, Nishimoto K, Yoshimoto S. Relationship between molecular structures of sugars and their ability to stimulate the release of glucagon-like peptide-1 from canine ileal loops. Acta Endocrinol (Copenh) 1990;123:
Discussion & Conclusion
Discussion & Conclusion 7. Discussion DPP-4 inhibitors augment the effects of incretin hormones by prolonging their half-life and represent a new therapeutic approach for the treatment of type 2 diabetes
More informationSitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP
Sitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP KEY POINTS sitagliptin (Januvia) is a DPP-4 inhibitor that blocks the breakdown of the
More informationEffect of macronutrients and mixed meals on incretin hormone secretion and islet cell function
Effect of macronutrients and mixed meals on incretin hormone secretion and islet cell function Background. Following meal ingestion, several hormones are released from the gastrointestinal tract. Some
More informationManagement of Type 2 Diabetes
Management of Type 2 Diabetes Pathophysiology Insulin resistance and relative insulin deficiency/ defective secretion Not immune mediated No evidence of β cell destruction Increased risk with age, obesity
More informationScope. History. History. Incretins. Incretin-based Therapy and DPP-4 Inhibitors
Plasma Glucose (mg/dl) Plasma Insulin (pmol/l) Incretin-based Therapy and Inhibitors Scope Mechanism of action ผศ.ดร.นพ.ว ระเดช พ ศประเสร ฐ สาขาว ชาโภชนว ทยาคล น ก ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล
More informationDisclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare
Disclosure Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare Spring Therapeutics Update 2011 CSHP BC Branch Anar Dossa BScPharm Pharm D CDE April 20, 2011
More informationPractical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010
Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE Robert R. Henry, MD Authors and Disclosures CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Introduction Type 2 diabetes
More information22 Emerging Therapies for
22 Emerging Therapies for Treatment of Type 2 Diabetes Siddharth N Shah Abstract: The prevalence of Diabetes is progressively increasing world-wide and the growth of the disease in our country is phenomenal.
More information(Incretin) ( glucagon-like peptide-1 GLP-1 ) GLP-1. GLP-1 ( dipeptidyl peptidase IV DPP IV ) GLP-1 DPP IV GLP-1 exenatide liraglutide FDA 2 2 2
007 18 189-194 (Incretin) Incretin ( ) -1 ( glucagon-like peptide-1 ) ( dipeptidyl peptidase IV ) liraglutide FDA ( Type diabetes mellitus ) -1 ( Glucagon-like peptide-1, ) ( Incretin ) ( Dipeptidyl peptidase
More informationDiabetes 2013: Achieving Goals Through Comprehensive Treatment. Session 2: Individualizing Therapy
Diabetes 2013: Achieving Goals Through Comprehensive Treatment Session 2: Individualizing Therapy Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism
More informationNew and Emerging Therapies for Type 2 DM
Dale Clayton MHSc, MD, FRCPC Dalhousie University/Capital Health April 28, 2011 New and Emerging Therapies for Type 2 DM The science of today, is the technology of tomorrow. Edward Teller American Physicist
More informationMegan Lawless. Journal Club. January 20 th, 2011
Megan Lawless Journal Club January 20 th, 2011 Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1 Proceedings of the National Academy of Sciences September 2007 Abstract
More informationMy Journey in Endocrinology. Samuel Cataland M.D
My Journey in Endocrinology Samuel Cataland M.D. 1968-2015 Drs Berson M.D. Yalow phd Insulin Radioimmunoassay Nobel Prize Physiology or Medicine 1977 Rosalyn Yalow: Radioimmunoassay Technology Andrew Schally
More informationSingle administration of vildagliptin attenuates postprandial hypertriglyceridemia and endothelial dysfunction in normoglycemic individuals
84 Single administration of vildagliptin attenuates postprandial hypertriglyceridemia and endothelial dysfunction in normoglycemic individuals KAORU NOGUCHI 1, MINORU HIROTA 1, TORU MIYOSHI 2, YOSHINORI
More informationNIH Public Access Author Manuscript Diabetologia. Author manuscript; available in PMC 2014 February 01.
NIH Public Access Author Manuscript Published in final edited form as: Diabetologia. 2013 February ; 56(2): 231 233. doi:10.1007/s00125-012-2788-6. Lipotoxicity impairs incretin signalling V. Poitout 1,2
More informationT2DM is a global epidemic with
: a new option for the management of type 2 diabetes Marc Evans MRCP, MD, Consultant Diabetologist, Llandough Hospital, Cardiff Incretin-based therapies for the treatment of diabetes mellitus (T2DM) present
More informationAdditive Effects of Miglitol and Anagliptin on Insulin-Treated Type 2 Diabetes Mellitus: A Case Study
Clin Drug Investig (2015) 35:141 147 DOI 10.1007/s40261-014-0260-8 CASE REPORT Additive Effects of Miglitol and Anagliptin on Insulin-Treated Type 2 Diabetes Mellitus: A Case Study Miyako Kishimoto Mitsuhiko
More informationGLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
GLP-1 agonists Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What do GLP-1 agonists do? Physiology of postprandial glucose regulation Meal ❶ ❷ Insulin Rising plasma
More informationBio& 242 Unit 1 / Lecture 4
Bio& 242 Unit 1 / Lecture 4 system: Gastric hormones GASTRIN: Secretion: By enteroendocrine (G) in gastric pits of the mucosa. Stimulus: Stomach distention and acid ph of chyme causes Gastrin. Action:
More informationHyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus
Diabetologia (2005) 48: 1168 1172 DOI 10.1007/s00125-005-1749-8 ARTICLE E. Mannucci. L. Pala. S. Ciani. G. Bardini. A. Pezzatini. I. Sposato. F. Cremasco. A. Ognibene. C. M. Rotella Hyperglycaemia increases
More informationDietary Fibres Soluble Fibres: can be.. Insoluble Fibres : can be..
Dietary Fibres The fraction of edible parts of plants or analogous carbohydrates that are: Resistant to digestion and absorption in the human small intestine with.. Complete or partial fermentation in
More informationIntact Glucagon-like Peptide-1 Levels are not Decreased in Japanese Patients with Type 2 Diabetes
Or i g i n a l Advance Publication Intact Glucagon-like Peptide-1 Levels are not Decreased in Japanese Patients with Type 2 Diabetes Soushou Lee*, Daisuke Yabe**, Kyoko Nohtomi*, Michiya Takada*, Ryou
More informationla prise en charge du diabète de
N21 XIII Congrès National de Diabétologie, 29 mai 2011, Alger Intérêt et place des Anti DPP4 dans la prise en charge du diabète de type 2 Nicolas PAQUOT, MD, PhD CHU Sart-Tilman, Université de Liège Belgique
More informationThe Mediterranean Diet: HOW and WHY It Works So Well for T2DM
The Mediterranean Diet: HOW and WHY It Works So Well for T2DM Susan L. Barlow, RD, CDE. Objectives 1. Discuss the effects of meal size on GLP-1 concentrations. 2. Compare and contrast the specific effects
More informationTargeting simultaneously GLP-1, GIP and glucagon receptors : a new paradigm for treating obesity and diabetes
SHORT COMMENT FOR NATURE REVIEWS ENDOCRINOLOGY Targeting simultaneously GLP-1, GIP and glucagon receptors : a new paradigm for treating obesity and diabetes André J. SCHEEN (1), Nicolas PAQUOT (2) (1)
More informationKazutaka Aoki 1), 2), Hiroshi Kamiyama 2), Kiyomi Masuda 2), Kazunari Kamiko 2), Yoshihiko Noguchi 2), Kazuki Tajima 2) and Yasuo Terauchi 2)
Endocrine Journal 2014, 61 (3), 249-256 Or i g i n a l Effects of miglitol, vildagliptin, or their combination on serum insulin and peptide YY levels and plasma glucose, cholecystokinin, ghrelin, and obestatin
More informationDiabetes mellitus. Treatment
Diabetes mellitus Treatment Recommended glycemic targets for the clinical management of diabetes(ada) Fasting glycemia: 80-110 mg/dl Postprandial : 100-145 mg/dl HbA1c: < 6,5 % Total cholesterol: < 200
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationMae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville
Mae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville Pathogenesis of Diabetes Mellitus (DM) Criteria for the diagnosis
More informationGlucagon-like peptide-1 secretion by direct stimulation of L cells with luminal sugar vs non-nutritive sweetener
ORIGINAL ARTICLE Glucagon-like peptide-1 secretion by direct stimulation of L cells with luminal sugar vs non-nutritive sweetener Kenichi Sakurai 1,2 *, Eun Young Lee 3, Asuka Morita 3, Sadao Kimura 4,
More informationadenosine triphosphate-sensitive K[ Citation Journal of Diabetes Investigation ( modifications or adaptations are ma
Fructose induces glucose-dependent Titleglucagon-like peptide-1 and insulin adenosine triphosphate-sensitive K[ Seino, Yusuke; Ogata, Hidetada; Mae Author(s) Takako; Iida, Atsushi; Harada, Nori Susumu;
More informationType 2 DM in Adolescents: Use of GLP-1 RA. Objectives. Scope of Problem: Obesity. Background. Pathophysiology of T2DM
Type 2 DM in Adolescents: Use of GLP-1 RA Objectives Identify patients in the pediatric population with T2DM that would potentially benefit from the use of GLP-1 RA Discuss changes in glycemic outcomes
More informationSociety for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery
Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery Girish P. Joshi, MB BS, MD, FFARCSI Anesthesia & Analgesia
More informationTherapeutic strategy to reduce Glucagon secretion
Clinical focus on glucagon: α-cell as a companion of β-cell Therapeutic strategy to reduce Glucagon secretion Sunghwan Suh Dong-A University Conflict of interest disclosure None Committee of Scientific
More informationZhong Chen, Xiaoying Fu, Jian Kuang *, Ju Chen, Hongmei Chen, Jianhao Pei and Huazhang Yang
Chen et al. BMC Endocrine Disorders (2016) 16:55 DOI 10.1186/s12902-016-0133-7 RESEARCH ARTICLE Open Access Single-dose acarbose decreased glucose-dependent insulinotropic peptide and glucagon levels in
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More informationDiabetes: What is the scope of the problem?
Diabetes: What is the scope of the problem? Elizabeth R. Seaquist MD Division of Endocrinology and Diabetes Department of Medicine Director, General Clinical Research Center Pennock Family Chair in Diabetes
More informationAbstract. Effect of sitagliptin on glycemic control in patients with type 2 diabetes. Introduction. Abbas Mahdi Rahmah
Effect of sitagliptin on glycemic control in patients with type 2 diabetes Abbas Mahdi Rahmah Correspondence: Dr. Abbas Mahdi Rahmah Consultant Endocrinologist, FRCP (Edin) Director of Iraqi National Diabetes
More informationSweetness and Glycaemic Regulation. (A focus on gut related and physiological aspects) John McLaughlin Manchester University
Sweetness and Glycaemic Regulation (A focus on gut related and physiological aspects) John McLaughlin Manchester University Disclosures No personal conflicts of interest Funding from BBSRC, including Cargill
More informationInitially more rapid small intestinal glucose delivery increases plasma. insulin, GIP and GLP-1, but does not improve overall glycemia in
Articles in PresS. Am J Physiol Endocrinol Metab (May 10, 2005). doi:10.1152/ajpendo.00099.2005 E-00099-2005.R1 Final accepted version 1 Initially more rapid small intestinal glucose delivery increases
More informationDiabetes Oral Agents Pharmacology. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
Diabetes Oral Agents Pharmacology University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 Learning Objectives Understand the role of the utilization of free
More informationChanging Diabetes: The time is now!
Midwest Cardiovascular Research Foundation Welcomes DANITA HARRISON, ARNP Ms. Harrison discloses speaking relationships with Lilly, Novo Nordisk and Pfizer. Changing Diabetes: The time is now! Danita Harrison
More informationSecretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
Diabetologia (211) 54:1 1 DOI 1.17/s125-1-196-4 REVIEW Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? M. A. Nauck & I. Vardarli & C. F. Deacon & J. J. Holst
More informationSpontaneously Diabetic Torii Lepr fa (SDT Fatty) Rat: A Novel Model of Obese Type 2 Diabetes
30 The Open Diabetes Journal, 2011, 4, 30-36 Open Access Spontaneously Diabetic Torii Lepr fa (SDT Fatty) Rat: A Novel Model of Obese Type 2 Diabetes Sumiaki Fukuda, Katsuhiro Miyajima, Tomohiko Sasase
More informationWhat s New in Diabetes Treatment. Disclosures
What s New in Diabetes Treatment Shiri Levy M.D. Henry Ford Hospital Senior Staff Physician Service Chief, West Bloomfield Hospital Endocrinology, Metabolism, Bone and Mineral Disorders Disclosures None
More informationGLYXAMBI (empagliflozin-linagliptin) oral tablet
GLYXAMBI (empagliflozin-linagliptin) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This
More informationOral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects 1 4
Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects 1 4 Jerry R Greenfield, I Sadaf Farooqi, Julia M Keogh, Elana
More informationTypes of Diabetes that the Dipeptidyl Peptidase-4 Inhibitor May Act Effectively and Safely
The Open Diabetes Journal, 2011, 4, 1-5 1 Open Access Types of Diabetes that the Dipeptidyl Peptidase-4 Inhibitor May Act Effectively and Safely Hidekatsu Yanai * and Hiroki Adachi Department of Internal
More informationINJECTABLE THERAPY FOR THE TREATMENT OF DIABETES
INJECTABLE THERAPY FOR THE TREATMENT OF DIABETES ARSHNA SANGHRAJKA DIABETES SPECIALIST PRESCRIBING PHARMACIST OBJECTIVES EXPLORE THE TYPES OF INSULIN AND INJECTABLE DIABETES TREATMENTS AND DEVICES AVAILABLE
More informationElectronic Supplementary Material to the article entitled Altered pattern of the
Electronic Supplementary Material to the article entitled Altered pattern of the incretin effect as assessed by modelling in individuals with glucose tolerance ranging from normal to diabetic Integrated
More informationDPP-4 inhibitor. The new class drug for Diabetes
DPP-4 inhibitor The new class drug for Diabetes 1 Cause of Death in Korea 1 st ; Neoplasm 2 nd ; Cardiovascular Disease 3 rd ; Cerebrovascular Disease Diabetes 2 Incidence of Fatal or Nonfatal MI During
More informationManagement of Type 2 Diabetes. Why Do We Bother to Achieve Good Control in DM2. Insulin Secretion. The Importance of BP and Glucose Control
Insulin Secretion Management of Type 2 Diabetes DG van Zyl Why Do We Bother to Achieve Good Control in DM2 % reduction 0-5 -10-15 -20-25 -30-35 -40 The Importance of BP and Glucose Control Effects of tight
More informationUpdate on Diabetes Mellitus
Update on Diabetes Mellitus Treatment: Targeting the Incretin System Overview Underlying defects with Type 2 diabetes Importance of managing postprandial glucose control Amylin Incretin Hormones New therapies
More informationThe enteroinsular axis in the pathogenesis of prediabetes and diabetes in humans
The enteroinsular axis in the pathogenesis of prediabetes and diabetes in humans Young Min Cho, MD, PhD Division of Endocrinology and Metabolism Seoul National University College of Medicine Plasma glucose
More informationEXENDIN-4 IS A 39-amino acid reptilian peptide that
0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(7):3469 3473 Printed in U.S.A. Copyright 2004 by The Endocrine Society doi: 10.1210/jc.2003-032001 Exendin-4 Normalized Postcibal
More informationCharacterization of GLP-1 Effects on -Cell Function After Meal Ingestion in Humans
Emerging Treatments and Technologies O R I G I N A L A R T I C L E Characterization of GLP-1 Effects on -Cell Function After Meal Ingestion in Humans BO AHRÉN, MD, PHD 1 JENS J. HOLST, MD, PHD 2 ANDREA
More informationINJECTABLE THERAPIES IN DIABETES. Barbara Ann McKee Diabetes Specialist Nurse
INJECTABLE THERAPIES IN DIABETES Barbara Ann McKee Diabetes Specialist Nurse 1 Aims of the session Describe the different injectable agents for diabetes and when they would be used. Describe some common
More informationDefective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients
Diabetologia (2002) 45:1111 1119 DOI 10.1007/s00125-002-0878-6 Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients T. Vilsbøll 1, 2, T. Krarup
More informationGut hormones KHATTAB
Gut hormones PROF:ABD ALHAFIZ HASSAN KHATTAB Gut as an endocrine gland The talk will cover the following : Historical background. Why this subject is chosen. Gastro-intestinal hormones and their function.
More informationGLUCAGON LIKE PEPTIDE (GLP) 1 AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES, WEIGHT CONTROL AND CARDIOVASCULAR PROTECTION.
GLUCAGON LIKE PEPTIDE (GLP) 1 AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES, WEIGHT CONTROL AND CARDIOVASCULAR PROTECTION. Patricia Garnica MS, ANP-BC, CDE, CDTC Inpatient Diabetes Nurse Practitioner North
More informationTreatment Options for Diabetes: An Update
Treatment Options for Diabetes: An Update A/Prof. Marg McGill Manager, Diabetes Centre Dr. Ted Wu Staff Specialist Endocrinologist Diabetes Centre Centre of Health Professional Education Education Provider
More informationVICTOSA and Renal impairment DR.R.S.SAJAD
VICTOSA and Renal impairment DR.R.S.SAJAD February 2019 Main effect of GLP-1 is : Stimulating glucose dependent insulin release from the pancreatic islets. Slow gastric emptying Inhibit inappropriate
More informationCurrent Status of Incretin Based Therapies in Type 2 Diabetes
Current Status of Incretin Based Therapies in Type 2 Diabetes DR.M.Mukhyaprana Prabhu Professor of Internal Medicine Kasturba Medical College, Manipal, Manipal University, India 2 nd International Endocrine
More informationNewer Drugs in the Management of Type 2 Diabetes Mellitus
Newer Drugs in the Management of Type 2 Diabetes Mellitus Dr. C. Dinesh M. Naidu Professor of Pharmacology, Kamineni Institute of Medical Sciences, Narketpally. 1 Presentation Outline Introduction Pathogenesis
More informationComparison of Dissolution and Pharmacokinetics of Vildagliptin Modified Release Tablets
International Journal of ChemTech Research CODEN (USA): IJCRGG, ISSN: 0974-4290, ISSN(Online):2455-9555 Vol.11 No.11, pp 318-322, 2018 Comparison of Dissolution and Pharmacokinetics of Vildagliptin Modified
More informationNEW DRUG THERAPY FOR TYPE 2 DIABETES MELLITUS: DPP-IV INHIBITORS
Review Article NEW DRUG THERAPY FOR TYPE 2 DIABETES MELLITUS: DPP-IV INHIBITORS Kulkarni Vivek S*, Dr. Senthil Kumar G.P 2, Lele Manish D 2, Gaikwad Dinanath T 1, Patil Manoj D 1, Gavitre Bhaskar B 1,
More informationDipeptidyl-peptidase IV inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrations
ORIGINAL ARTICLE Dipeptidyl-peptidase IV inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrations Takafumi Senmaru 1, Michiaki Fukui 1 *, Kanae Kobayashi
More informationNeuroprotective properties of GLP-1 - a brief overview. Michael Gejl Jensen, MD Dept. Of Pharmacology, AU
Neuroprotective properties of GLP-1 - a brief overview Michael Gejl Jensen, MD Dept. Of Pharmacology, AU mg@farm.au.dk Agenda Glucagon-like peptide (GLP-1) GLP-1 and neuronal activity GLP-1 in disease-specific
More informationBiology 12 Unit 5 Pretest
Biology Unit 5 Pretest Name: Date: Block:. Chewing aids digestion by A. stimulating release of bile B. increasing surface area of food C. breaking up polymers into monomers D. stimulating water absorption.
More informationEffects of the naturally-occurring disaccharides, palatinose and sucrose, on incretin secretion in healthy non-obese subjects
RIGINAL ARTICLE Effects of the naturally-occurring disaccharides, palatinose and sucrose, on incretin secretion in healthy non-obese subjects Aya Maeda 1, Jun-ichiro Miyagawa 1, Masayuki Miuchi 1, Etsuko
More informationGLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) s (Byetta/exenatide, Bydureon/ exenatide extended-release, Tanzeum/albiglutide, Trulicity/dulaglutide, and Victoza/liraglutide) Step Therapy
More informationExpanding Treatment Options for Diabetes: GLP-1 Receptor Agonists. Copyright
CLINICAL Viewpoint Expanding Treatment Options for Diabetes: GLP-1 Receptor Agonists Advancements in Diabetes Management: A Canadian Diabetes Steering Committee Report Copyright Not for Sale or Commercial
More informationOral L-Arginine Stimulates GLP-1 Secretion to Improve Glucose Tolerance in Male Mice. of L-arginine for glucose metabolism.
B R I E F R E S E A R C H R E P O R T Oral L-Arginine Stimulates GLP-1 Secretion to Improve Glucose Tolerance in Male Mice Christoffer Clemmensen, Sanela Smajilovic, Eric P. Smith, Stephen C. Woods, Hans
More informationThe Small Intestine. The pyloric sphincter at the bottom of the stomach opens, squirting small amounts of food into your small intestine.
The Small Intestine The pyloric sphincter at the bottom of the stomach opens, squirting small amounts of food into your small intestine. approximately six metres (the longest section of your digestive
More informationARTICLE. P. V. Højberg & T. Vilsbøll & R. Rabøl & F. K. Knop & M. Bache & T. Krarup & J. J. Holst & S. Madsbad
Diabetologia (29) 52:199 27 DOI 1.17/s125-8-1195-5 ARTICLE Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic
More informationENERGY FROM INGESTED NUTREINTS MAY BE USED IMMEDIATELY OR STORED
QUIZ/TEST REVIEW NOTES SECTION 1 SHORT TERM METABOLISM [METABOLISM] Learning Objectives: Identify primary energy stores of the body Differentiate the metabolic processes of the fed and fasted states Explain
More informationShinya Kawamoto *, Ryo Koda, Yuji Imanishi, Atsunori Yoshino and Tetsuro Takeda
Kawamoto et al. Renal Replacement Therapy (2016) 2:39 DOI 10.1186/s41100-016-0050-2 RESEARCH Open Access The dipeptidyl peptidase-4 inhibitor may improve the insulin secretion in type 2 diabetes patients
More informationPancreatic b-cell Dysfunction in Type 2 Diabetes ZIAD KAHWASH, M.D. Insulin resistance: Defects in Insulin Signaling
Plasma insulin (mu/ml) ZIAD KAHWASH, M.D. resistance: Defects in Signaling Increased glucose production Glucose Insufficient glucose disposal X Liver glucagon insulin Pancreas Peripheral tissues (skeletal
More informationDrug Class Monograph
Drug Class Monograph Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drugs: alogliptin, alogliptin/metformin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin),
More informationDipeptidyl Peptidase-4 Inhibition by Vildagliptin and the Effect on Insulin Secretion and Action in Response to Meal Ingestion in Type 2 Diabetes
Clinical Care/Education/Nutrition/Psychosocial Research O R I G I N A L A R T I C L E Dipeptidyl Peptidase-4 Inhibition by Vildagliptin and the Effect on Insulin Secretion and Action in Response to Meal
More informationShohei Sakata, Yasuko Mera, Yukiharu Kuroki, Reiko Nashida, Makoto Kakutani, and Takeshi Ohta
Diabetes Research Volume 214, Article ID 89639, 7 pages http://dx.doi.org/1.1155/214/89639 Research Article Therapy of an Intestine-Specific Inhibitor of Microsomal Triglyceride Transfer Protein and Peroxisome
More informationRPCC Pharmacy Forum. The Type 2 Diabetes Issue. Type 2 Diabetes: The Basics
Nov/Dec 2015 Issue 11 RPCC Pharmacy Forum Special Interest Articles: Diabetes Medication Chart Insulin Chart Afreeza Did you know? Exanatide, marketed as Byetta, is the synthetic form of exendin-4, which
More informationNew Treatments for Type 2 diabetes. Nandini Seevaratnam April 2016 Rushcliffe Patient Forum
New Treatments for Type 2 diabetes Nandini Seevaratnam April 2016 Rushcliffe Patient Forum Overview Growing population of Type 2 diabetes Basic science on what goes wrong Current treatments Why there is
More informationEarly treatment for patients with Type 2 Diabetes
Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona
More informationBritish Journal of Nutrition
, page 1 of 5 q The Authors 2013 doi:10.1017/s0007114513000731 Endogenous plasma glucagon-like peptide-1 following acute dietary fibre consumption Caroline L. Bodinham*, Najlaa M. Al-Mana, Leanne Smith
More informationEAT TO LIVE: THE ROLE OF THE PANCREAS. Felicia V. Nowak, M.D., Ph.D. Ohio University COM 22 January, 2008
EAT TO LIVE: THE ROLE OF THE PANCREAS Felicia V. Nowak, M.D., Ph.D. Ohio University COM 22 January, 2008 THE ROLE OF THE PANCREAS Exocrine pancreas Endocrine pancreas THE ROLE OF THE PANCREAS EXOCRINE
More informationRole of incretins in the treatment of type 2 diabetes
Role of incretins in the treatment of type 2 diabetes Jens Juul Holst Department of Medical Physiology Panum Institute University of Copenhagen Denmark Diabetes & Obesity Spanish Society of Internal Medicine
More informationOptimal glucose control. DM Treatment. Glucose Control one out of many. Many guidelines: Confusing. Theorectically easy
DM Treatment How to Achieve Optimal Glycaemic Control The Tung Wah Eastern Hospital Experience of DM Share Care Experience Optimal glucose control Theorectically easy More challenging in the real world
More informationTreating Type 2 Diabetes with Bariatric Surgery. Goal of Treating T2DM. Remission of T2DM with Bariatric
Treating Type 2 Diabetes with Bariatric Surgery Number (in Millions) of Persons with Diagnosed Diabetes, United States, 198 25 The number of Americans with diabetes increased from 5.6 to 15.8 million Guilherme
More informationSitagliptin: A component of incretin based therapy. Rezvan Salehidoost, M.D., Endocrinologist
Sitagliptin: A component of incretin based therapy Rezvan Salehidoost, M.D., Endocrinologist Agenda Mode of Action Evidences for sitagliptine cardiovascular safety of sitagliptin Ramadan study Impact of
More informationModulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes. Overview. Prevalence of Overweight in the U.S.
Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Geneva Clark Briggs, PharmD, BCPS Overview Underlying defects with Type 2 diabetes Importance of managing postprandial glucose
More informationModulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes
Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Geneva Clark Briggs, PharmD, BCPS Adjunct Professor at University of Appalachia College of Pharmacy Clinical Associate, Medical
More informationDiabetes: Three Core Deficits
Diabetes: Three Core Deficits Fat Cell Dysfunction Impaired Incretin Function Impaired Appetite Suppression Obesity and Insulin Resistance in Muscle and Liver Hyperglycemia Impaired Insulin Secretion Islet
More informationProfessor Rudy Bilous James Cook University Hospital
Professor Rudy Bilous James Cook University Hospital Rate per 100 patient years Rate per 100 patient years 16 Risk of retinopathy progression 16 Risk of developing microalbuminuria 12 12 8 8 4 0 0 5 6
More informationCurrent therapies for type 2 diabetes
Reviews/Commentaries/ADA R E V I E W A R T I C L E Statements Emerging Therapies Mimicking the Effects of Amylin and Glucagon-Like Peptide 1 MATTHEW C. RIDDLE, MD 1 DANIEL J. DRUCKER, MD 2 Current therapies
More informationGLP-1 Receptor Agonists and SGLT-2 Inhibitors. Debbie Hicks
GLP-1 Receptor Agonists and SGLT-2 Inhibitors Debbie Hicks Prescribing and Adverse Event reporting information is available at this meeting from the AstraZeneca representative The views expressed by the
More informationDipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol
Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationSoliqua (insulin glargine and lixisenatide), Xultophy (insulin degludec and liraglutide)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.48 Subject: Insulin GLP-1 Combinations Page: 1 of 5 Last Review Date: September 15, 2017 Insulin GLP-1
More informationDiv. of Endocrinology and Metabolism Konyang University, School of Medicine. Byung-Joon Kim M.D., Ph.D.
Diabetes and Thyroid Center Div. of Endocrinology and Metabolism Konyang University, School of Medicine Byung-Joon Kim M.D., Ph.D. Background Incretin effect and GLP 1 Receptor in L cells TGR5 receptor
More information